Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Adam Rosenthal, Star Therapeutics CEO June 8, 2026 07:03 AM EDT StartupsDeals In­cyte to buy bleed­ing dis­or­der biotech Ve­ga Ther­a­peu­tics in $1.25B up­front deal Kyle LaHucik Biotech Correspondent In­cyte plans to spend $1.25 bil­lion up­front to buy Star Ther­a­peu­tics’ sub­sidiary Ve­ga Ther­a­peu­tics and its Phase 3 bleed­ing dis­or­der can­di­date, the com­pa­nies said Mon­day … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER